Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

358
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
358
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.1K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.1K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

469
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
469
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

355
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
355
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

3.5K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.5K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

282
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
282

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Morphologic evaluation in fibrotic hypersensitivity pneumonitis: the era of quantitative CT is upon us.

Annals of the American Thoracic Society·2026
Same author

Progressive pulmonary fibrosis: a state-of-the-art review.

The European respiratory journal·2026
Same author

Assessment of noninvasive parameters prior to diagnosis of pulmonary hypertension in patients with fibrotic interstitial lung disease.

ERJ open research·2026
Same author

Changes in Interstitial Lung Disease Nomenclature.

Archivos de bronconeumologia·2026
Same author

Response.

Chest·2026
Same author

A statistical model for lung function trajectory and mortality in patients with fibrotic interstitial lung disease.

American journal of respiratory and critical care medicine·2026

Related Experiment Video

Updated: Oct 29, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

474

The progressive fibrotic phenotype in current clinical practice.

Athol U Wells1,2, Kevin K Brown3, Vincent Cottin4

  • 1Interstitial Lung Disease Unit, Royal Brompton Hospital.

Current Opinion in Pulmonary Medicine
|July 7, 2021
PubMed
Summary

The progressive fibrotic phenotype (PFP) affects many patients with lung disease. Recent antifibrotic trial data offers new management options, but accurate diagnosis and progression criteria remain crucial for effective treatment.

More Related Videos

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

242
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.4K

Related Experiment Videos

Last Updated: Oct 29, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

474
Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

242
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.4K

Area of Science:

  • Pulmonology
  • Fibrotic Lung Diseases
  • Clinical Medicine

Background:

  • The progressive fibrotic phenotype (PFP) describes patients with fibrotic lung diseases who worsen despite standard care.
  • PFP represents a significant clinical challenge for both patients and healthcare providers.
  • Understanding PFP is essential for managing lung fibrosis progression.

Purpose of the Study:

  • To review recent data relevant to clinical uncertainties surrounding PFP.
  • To emphasize the importance of accurate diagnosis in managing fibrotic lung diseases.
  • To analyze the efficacy of antifibrotic therapies in various fibrotic lung conditions.

Main Methods:

  • Review of clinical data defining the PFP.
  • Analysis of pivotal antifibrotic trials, including disease range and efficacy signals.
  • Examination of treatment effects in individual diseases and validation of PFP progression criteria.

Main Results:

  • Antifibrotic trial findings can now be applied to non-idiopathic pulmonary fibrosis lung diseases.
  • Accurate initial diagnosis is critical, refuting the notion that it matters less due to new trial data.
  • Efficacy signals from pivotal trials provide valuable insights into treatment effects.

Conclusions:

  • Clinicians can utilize recent antifibrotic trial findings for non-IPF fibrotic lung diseases.
  • Understanding diagnosis, progression measures, and trial limitations is key to applying new data.
  • Uncertainties remain regarding optimal traditional management and precise progression definitions for antifibrotic therapy initiation.